July 22, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Adults with ADHD and comorbid anxiety experienced improvements in both with centanafadine, according to a press release from Otsuka Pharmaceutical. Currently under investigation, centanafadine is a norepinephrine, dopamine and serotonin reuptake inhibitor that Otuska called first-in-class.
July 22, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity…

The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity…

Simtriyo, the first approved ADHD drug to inhibit norepinephrine, dopamine and serotonin reuptake, improved symptoms within a…

L'Otsuka Pharmaceutical Development & Commercializatio annunciato l'approvazione da parte della FDA della centanafadina orale…

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the…